{"id":"placebo-plus-dexamethasone-hfa","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Dysphonia"}]},"_chembl":{"chemblId":"CHEMBL1697787","moleculeType":"Small molecule","molecularWeight":"528.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone is a synthetic glucocorticoid that exerts anti-inflammatory and immunosuppressive effects by activating intracellular glucocorticoid receptors, which translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced immune cell activation and infiltration. The HFA formulation is a metered-dose inhaler delivery system for pulmonary administration.","oneSentence":"Dexamethasone is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:20.401Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma or chronic obstructive pulmonary disease (COPD) — Phase 3 trial indication likely respiratory inflammation"}]},"trialDetails":[{"nctId":"NCT01033825","phase":"PHASE3","title":"Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-01","conditions":"Perennial Allergic Rhinitis","enrollment":310}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Decadron"],"phase":"phase_3","status":"active","brandName":"Placebo plus Dexamethasone HFA","genericName":"Placebo plus Dexamethasone HFA","companyName":"Sumitomo Pharma America, Inc.","companyId":"sumitomo-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamethasone is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Asthma or chronic obstructive pulmonary disease (COPD) — Phase 3 trial indication likely respiratory inflammation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}